The Treatment Action Group’s 2014 Pipeline Report released in conjunction with the 20th International AIDS Conference last week devotes three sections to the outlook for better and more accessible treatment for hepatitis C, examining the promise of new direct acting antiviral treatments, starting with sofosbuvir (marketed by Gilead pharmaceutical company as Sovaldi) being eclipsed by […]
HIV
By Richard Ngethe, MBA, Data.FI As a data clerk in Kenya in 2005, my challenge was to work at rural hospitals digitizing client-level longitudinal data for […]
Tuberculosis
The publication of trial data showing a four-month treatment regimen for tuberculosis that is not resistant to first-line medicines as effective as the currently widely prescribed […]
Research & Development
By Mitchell Warren, executive director, AVAC In February 2020, just as the COVID pandemic began its rapid global spread, a major HIV vaccine trial called HVTN […]
Policy
By Karen Carvajal, M.D. Over the course of human history we have come a long way in our fight against the threat of infectious diseases and, […]